NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
-20.18%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$1.95B
AUM Growth
+$1.95B
(-44%)
Cap. Flow
-$601M
Cap. Flow
% of AUM
-30.89%
Top 10 Holdings %
Top 10 Hldgs %
66.18%
Holding
59
New
2
Increased
9
Reduced
4
Closed
2
Top Buys
| 1 |
Trevi Therapeutics
TRVI
|
$32M |
| 2 |
IVA
Inventiva
IVA
|
$24.2M |
| 3 |
Palo Alto Networks
PANW
|
$15.4M |
| 4 |
Nkarta
NKTX
|
$8.21M |
| 5 |
Senti Biosciences
SNTI
|
$7.46M |
Top Sells
| 1 |
Robinhood
HOOD
|
$644M |
| 2 |
RGLS
Regulus Therapeutics
RGLS
|
$26.9M |
| 3 |
GNCA
Genocea Biosciences, Inc.
GNCA
|
$13M |
| 4 |
IonQ
IONQ
|
$12.8M |
| 5 |
Enliven Therapeutics
ELVN
|
$2.81M |
Sector Composition
| 1 | Healthcare | 69.32% |
| 2 | Technology | 12.48% |
| 3 | Consumer Staples | 11.56% |
| 4 | Industrials | 4.58% |
| 5 | Communication Services | 1.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
NeueHealth
NEUE
$59.2M
| $397M | 20.4% | 218,212,126 | – | – |
|
2
Coursera
COUR
$1.88B
| $225M | 11.56% | 15,867,769 | – | – |
|
|
3
IonQ
IONQ
$12.7B
| $115M | 5.93% | 26,350,067 -2,927,785 | -10% | -$12.8M |
|
4
Arcellx
ACLX
$3.85B
| $113M | 5.79% | 6,750,264 +312,500 | +5% | +$5.22M |
|
5
CRISPR Therapeutics
CRSP
$4.71B
| $96.6M | 4.96% | 1,590,002 | – | – |
|
6
Cloudflare
NET
$72.7B
| $82.1M | 4.22% | 1,877,510 | – | – |
|
7
Mirum Pharmaceuticals
MIRM
$3.71B
| $81.5M | 4.19% | 4,187,801 | – | – |
|
8
Monte Rosa Therapeutics
GLUE
$296M
| $74.5M | 3.83% | 7,703,205 | – | – |
|
|
BGRY
9
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $55.4M | 2.85% | 38,226,621 | – | – |
|
|
CTIC
10
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $48M | 2.47% | 8,047,228 +906,778 | +13% | +$5.41M |
|
|
11
Nkarta
NKTX
$151M
| $44M | 2.26% | 3,571,640 +666,666 | +23% | +$8.21M |
|
12
Aurinia Pharmaceuticals
AUPH
$1.58B
| $39.9M | 2.05% | 3,969,834 | – | – |
|
13
Savara
SVRA
$567M
| $36.7M | 1.88% | 24,137,931 | – | – |
|
|
14
Trevi Therapeutics
TRVI
$883M
| $32M | 1.64% | 11,373,174 +11,370,376 | +406,375% | +$32M |
|
|
DM
15
DELISTED
Desktop Metal, Inc.
DM
| $31.7M | 1.63% | 14,407,594 | – | – |
|
|
IVA
16
Inventiva
IVA
$861M
| $31.6M | 1.62% | 5,572,953 +4,274,253 | +329% | +$24.2M |
|
|
ADAP
17
Adaptimmune Therapeutics
ADAP
$15.6M
| $29M | 1.49% | 17,082,612 +1 | +0% | +$2 |
|
|
AVEO
18
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $25.9M | 1.33% | 3,952,957 | – | – |
|
|
OYST
19
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $25.7M | 1.32% | 5,925,287 | – | – |
|
20
Geron
GERN
$893M
| $25.3M | 1.3% | 16,318,681 | – | – |
|
21
BuzzFeed
BZFD
$72.6M
| $23.6M | 1.21% | 15,333,892 | – | – |
|
|
UTRS
22
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
| $23.5M | 1.21% | 10,001,937 | – | – |
|
|
VRNA
23
Verona Pharma
VRNA
$9.16B
| $21.4M | 1.1% | 5,108,563 | – | – |
|
24
Rhythm Pharmaceuticals
RYTM
$6.85B
| $20.4M | 1.05% | 4,912,306 | – | – |
|
|
AKUS
25
DELISTED
Akouos, Inc. Common Stock
AKUS
| $20.2M | 1.04% | 4,298,488 | – | – |
|